Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
Bridgebio Pharma Inc: The Vanguard Group amended its Schedule 13G to report 0 shares of Common Stock, representing 0% ownership. The filing notes an internal realignment effective January 12, 2026 that led Vanguard subsidiaries to report holdings separately.
Trimarchi Thomas reported acquisition or exercise transactions in this Form 4 filing.
BridgeBio Pharma, Inc. reported that its President and CFO, Thomas Trimarchi, received a grant of 59,041 restricted stock units (RSUs) of common stock as equity compensation. Each RSU represents a right to receive one share of common stock. The RSUs vest as to 1/16 of the underlying shares on May 16, 2026, and 1/16 each quarter thereafter, conditioned on his continued service. Following this grant, Trimarchi directly holds 395,626 shares of BridgeBio common stock.
BridgeBio Pharma, Inc. reported that Chief Accounting Officer Maricel Apuli received a grant of 14,170 restricted stock units (RSUs) of common stock as equity compensation. The award was made at no cash cost to Apuli and increases her direct holdings to 136,115 shares.
The RSUs vest over time, with 1/16 of the units scheduled to vest on May 16, 2026, and 1/16 vesting each quarter thereafter until fully vested, contingent on her continued service with BridgeBio or its subsidiaries. Each RSU converts into one share of common stock upon vesting, providing long-term, service-based incentive alignment.
BridgeBio Pharma, Inc. reported that Chief Executive Officer Neil Kumar received new equity awards on March 17, 2026. He was granted stock options for 40,570 shares of common stock at an exercise price of $70.94 per share, expiring on March 16, 2036.
He also received 104,313 restricted stock units (RSUs), each representing one share of common stock. Both the option and RSU awards vest in equal 1/16 installments beginning on May 16, 2026, then quarterly, as long as he continues serving the company or its subsidiaries.
BridgeBio Pharma CEO Neil Kumar reported insider sales executed by family trusts holding company stock. On March 12–13, 2026, trusts for which he is co‑trustee sold a total of 80,000 shares of BridgeBio common stock in open‑market transactions at prices around the high‑$60s to about $70.18 per share.
After these sales, one family irrevocable trust held 635,686 shares, a revocable trust held 4,438,447 shares, and Kumar also reported 234,451 shares held directly. The transactions were carried out under a pre‑arranged Rule 10b5‑1 sales plan, and Kumar disclaimed beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.
BBIO proposes the sale of 140,000 shares of Common stock as indicated on the notice.
The filing lists multiple prior 10b5-1 sales by related parties, including recent transactions by Kumar Haldea Revocable Trust and Neil Kumar on 03/12/2026 and 02/19/2026. Examples shown include 20,000 shares sold on 03/12/2026 and 28,053 shares sold on 02/19/2026.
BridgeBio Pharma director Hannah Valantine exercised stock options to acquire 8,671 shares of common stock at $27.36 per share on March 10, 2026. She then sold the same 8,671 shares at $72.00 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she holds 7,465 shares directly and 398 shares indirectly through her spouse.
Hannah A Valantine reported a Rule 144 notice to sell Common Stock. The filing shows a planned sale tied to a 03/10/2026 stock option exercise and reports a prior sale of 25,484 shares on 02/27/2026 for $1,717,779.60.
The transaction is listed through Morgan Stanley Smith Barney LLC, with the security identified as Common and the market noted as NASDAQ. The filing is a notice of proposed resale under Rule 144 rather than a Form 3/4 insider trade report.
BridgeBio Pharma, Inc. director Andrea Ellis exercised stock options and sold shares in a pre‑planned trade. On March 4, 2026, Ellis exercised options for 64,921 shares of common stock at $8.45 per share, converting a previously held stock option that had vested in three annual installments beginning on June 22, 2023 and ending on June 22, 2025. The same day, Ellis sold 64,921 shares of common stock at a weighted average price of $64.8681 per share, within a range of $64.255 to $65.21, under a Rule 10b5‑1 sales plan adopted on December 3, 2025, and held 18,589 shares directly afterward.